Browsing Psychosis by Title
Now showing items 1-16 of 16
-
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): A double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
(2017)Background: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. ... -
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: A double-blind, placebo-controlled trial
(2018)Background: A second antipsychotic is commonly added to clozapine to treat refractory schizophrenia, notwithstanding the limited evidence to support such practice. Methods: The efficacy and adverse effects of this ... -
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: The amicus study
(2017)Background: In around a third of people with schizophrenia, the illness responds poorly to standard treatment with antipsychotic medication. Clozapine is the only antipsychotic medication with robust evidence for effcacy ... -
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT
(2018)BACKGROUND: Very late-onset (aged & greater than 60 years) schizophrenia-like psychosis (VLOSLP) occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy or risks of antipsychotic treatment. ... -
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
(2016)Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes ... -
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
(2016)Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes ... -
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
(2018)Background: Very late (aged & greater than 60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We ... -
Audit of discharges from a regional service in the United Kingdom.
(2014)Aim As early intervention in psychosis (EI) continues to develop, clinical governance maintains an important role in the 'real world' analysis of services. This paper details an audit of all discharges from a regional ... -
Brief interventions and single sessions as stages in a change process for people with psychosis
(Routledge, 2015)In this chapter, the therapeutic benefits of single sessions and brief interventions for people with psychosis who are hard to engage are explored. Whilst such brief contact can be valuable for promoting engagement or as ... -
Effectiveness comparison of antipsychotics used in first-episode psychosis: A naturalistic cohort study
(2014)Introduction: Several studies have explored comparative effectiveness of first prescribed antipsychotics for FEP using time to treatment discontinuation as a proxy measure. Consistent differences are not demonstrated. We ... -
Electroconvulsive therapy for treatment-resistant schizophrenia
(2019)Background: Electroconvulsive therapy (ECT) involves the induction of a seizure by the administration of an electrical stimulus via electrodes usually placed bilaterally on the scalp and was introduced as a treatment for ... -
Exploring the experience of hearing voices from a first person perspective: a meta-ethnographic synthesis
(2014)Purpose. The purpose of this review was to identify, appraise, and synthesize thecurrent peer-reviewed qualitative literature which explores the phenomenon of hearing voices from a first person perspective. Methods. A ... -
Glutathione and glutamate in schizophrenia: a 7T MRS study
(2018)In schizophrenia, abnormal neural metabolite concentrations may arise from cortical damage following neuroinflammatory processes implicated in acute episodes. Inflammation is associated with increased glutamate, whereas ... -
How cognitive behavioural therapy can help in the treatment of schizophrenia
(2017)The perceptions and treatment of schizophrenia have changed radically in recent years. Today, alongside antipsychotic medications, the National Institute for Health and Care Excellence recommends the use of cognitive ... -
Long-term antidepressant treatment for negative symptoms in schizophrenia: The actions study
(2017)Background: The negative symptoms of schizophrenia represent defcien-cies in emotional responsiveness, motivation and socialization that tend to be persistent despite standard antipsychotic treatment. Two sub-domains of ... -
You can't spell schizophrenia without an 'I': how does the Early Intervention in Psychosis approach relate to the concept of schizophrenia as an ipseity disturbance?
(2013)Background and Aim: Operational approaches to psychiatric diagnosis have increased reliability, but the cost has been the reduction of diagnostic concepts to tick-box lists of objective symptoms. Some blame this for growing ...
